Improved opioid analgesic effect following opioid dose reduction

Yakov Vorobeychik, Lucy Chen, Mary Chasko Bush, Jianren Mao

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Introduction: Traditionally, opioids have been the cornerstone of therapy for patients suffering from cancer pain, regardless of the potential to develop opioid tolerance. In chronic pain patients who experience worsening pain despite increasing doses of opioids, the clinical role of opioid-induced hyperalgesia is gaining more recognition. Case: Presented here is the case of a 56-year-old man with recurrent squamous cell lung carcinoma and spinal metastases, suffering with intractable 8/10 pain on the visual analog scale in his chest, lower thoracic spine, and upper lumbar spine. He was admitted five times for pain control. In spite of escalating doses of oxycodone, morphine, and hydromorphone, the patient continued to experience severe pain. Also, he endured undesirable sedation, fatigue, and generalized weakness. The clinical picture suggested the possibility of opioid-induced hyperalgesia. We decreased the hydromorphone dose by 40-50% and started methadone. The patient's pain level dropped to a more acceptable 3/10. He was more alert, and his pain was tolerable until his death. Discussion: Opioid-induced hyperalgesia might be considered in a patient who has no evidence of disease progression, who is on clinically reasonable doses of opioids, and whose pain escalates as opioid doses are increased. A reduction of opioids and the addition of a low-dose N-methyl-D-aspartate receptor antagonist may provide a favorable clinical outcome in those patients who have failed to benefit from opioid rotation and other adjunctive pain treatments.

Original languageEnglish (US)
Pages (from-to)724-727
Number of pages4
JournalPain Medicine
Volume9
Issue number6
DOIs
StatePublished - Sep 1 2008

Fingerprint

Opioid Analgesics
Pain
Hyperalgesia
Hydromorphone
Spine
Thorax
Oxycodone
Methadone
Pain Measurement
N-Methyl-D-Aspartate Receptors
Chronic Pain
Morphine
Fatigue
Disease Progression
Squamous Cell Carcinoma
Neoplasm Metastasis
Lung
Therapeutics

All Science Journal Classification (ASJC) codes

  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Vorobeychik, Yakov ; Chen, Lucy ; Bush, Mary Chasko ; Mao, Jianren. / Improved opioid analgesic effect following opioid dose reduction. In: Pain Medicine. 2008 ; Vol. 9, No. 6. pp. 724-727.
@article{7c2a044742844e89a4f9fda942c19f23,
title = "Improved opioid analgesic effect following opioid dose reduction",
abstract = "Introduction: Traditionally, opioids have been the cornerstone of therapy for patients suffering from cancer pain, regardless of the potential to develop opioid tolerance. In chronic pain patients who experience worsening pain despite increasing doses of opioids, the clinical role of opioid-induced hyperalgesia is gaining more recognition. Case: Presented here is the case of a 56-year-old man with recurrent squamous cell lung carcinoma and spinal metastases, suffering with intractable 8/10 pain on the visual analog scale in his chest, lower thoracic spine, and upper lumbar spine. He was admitted five times for pain control. In spite of escalating doses of oxycodone, morphine, and hydromorphone, the patient continued to experience severe pain. Also, he endured undesirable sedation, fatigue, and generalized weakness. The clinical picture suggested the possibility of opioid-induced hyperalgesia. We decreased the hydromorphone dose by 40-50{\%} and started methadone. The patient's pain level dropped to a more acceptable 3/10. He was more alert, and his pain was tolerable until his death. Discussion: Opioid-induced hyperalgesia might be considered in a patient who has no evidence of disease progression, who is on clinically reasonable doses of opioids, and whose pain escalates as opioid doses are increased. A reduction of opioids and the addition of a low-dose N-methyl-D-aspartate receptor antagonist may provide a favorable clinical outcome in those patients who have failed to benefit from opioid rotation and other adjunctive pain treatments.",
author = "Yakov Vorobeychik and Lucy Chen and Bush, {Mary Chasko} and Jianren Mao",
year = "2008",
month = "9",
day = "1",
doi = "10.1111/j.1526-4637.2008.00501.x",
language = "English (US)",
volume = "9",
pages = "724--727",
journal = "Pain Medicine",
issn = "1526-2375",
publisher = "Wiley-Blackwell",
number = "6",

}

Improved opioid analgesic effect following opioid dose reduction. / Vorobeychik, Yakov; Chen, Lucy; Bush, Mary Chasko; Mao, Jianren.

In: Pain Medicine, Vol. 9, No. 6, 01.09.2008, p. 724-727.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Improved opioid analgesic effect following opioid dose reduction

AU - Vorobeychik, Yakov

AU - Chen, Lucy

AU - Bush, Mary Chasko

AU - Mao, Jianren

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Introduction: Traditionally, opioids have been the cornerstone of therapy for patients suffering from cancer pain, regardless of the potential to develop opioid tolerance. In chronic pain patients who experience worsening pain despite increasing doses of opioids, the clinical role of opioid-induced hyperalgesia is gaining more recognition. Case: Presented here is the case of a 56-year-old man with recurrent squamous cell lung carcinoma and spinal metastases, suffering with intractable 8/10 pain on the visual analog scale in his chest, lower thoracic spine, and upper lumbar spine. He was admitted five times for pain control. In spite of escalating doses of oxycodone, morphine, and hydromorphone, the patient continued to experience severe pain. Also, he endured undesirable sedation, fatigue, and generalized weakness. The clinical picture suggested the possibility of opioid-induced hyperalgesia. We decreased the hydromorphone dose by 40-50% and started methadone. The patient's pain level dropped to a more acceptable 3/10. He was more alert, and his pain was tolerable until his death. Discussion: Opioid-induced hyperalgesia might be considered in a patient who has no evidence of disease progression, who is on clinically reasonable doses of opioids, and whose pain escalates as opioid doses are increased. A reduction of opioids and the addition of a low-dose N-methyl-D-aspartate receptor antagonist may provide a favorable clinical outcome in those patients who have failed to benefit from opioid rotation and other adjunctive pain treatments.

AB - Introduction: Traditionally, opioids have been the cornerstone of therapy for patients suffering from cancer pain, regardless of the potential to develop opioid tolerance. In chronic pain patients who experience worsening pain despite increasing doses of opioids, the clinical role of opioid-induced hyperalgesia is gaining more recognition. Case: Presented here is the case of a 56-year-old man with recurrent squamous cell lung carcinoma and spinal metastases, suffering with intractable 8/10 pain on the visual analog scale in his chest, lower thoracic spine, and upper lumbar spine. He was admitted five times for pain control. In spite of escalating doses of oxycodone, morphine, and hydromorphone, the patient continued to experience severe pain. Also, he endured undesirable sedation, fatigue, and generalized weakness. The clinical picture suggested the possibility of opioid-induced hyperalgesia. We decreased the hydromorphone dose by 40-50% and started methadone. The patient's pain level dropped to a more acceptable 3/10. He was more alert, and his pain was tolerable until his death. Discussion: Opioid-induced hyperalgesia might be considered in a patient who has no evidence of disease progression, who is on clinically reasonable doses of opioids, and whose pain escalates as opioid doses are increased. A reduction of opioids and the addition of a low-dose N-methyl-D-aspartate receptor antagonist may provide a favorable clinical outcome in those patients who have failed to benefit from opioid rotation and other adjunctive pain treatments.

UR - http://www.scopus.com/inward/record.url?scp=50249130756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50249130756&partnerID=8YFLogxK

U2 - 10.1111/j.1526-4637.2008.00501.x

DO - 10.1111/j.1526-4637.2008.00501.x

M3 - Article

VL - 9

SP - 724

EP - 727

JO - Pain Medicine

JF - Pain Medicine

SN - 1526-2375

IS - 6

ER -